Introduction
The heart has sustained high energy demands and primarily relies on the oxidation of fatty acids (FA) ($60-90%). 1 During the transition process towards heart failure (HF), the cardiac substrate preference shifts to a greater reliance on glucose as substrate with a concomitant suppression of FA utilization. 1, 2 The metabolic shift towards glucose utilization has long been interpreted as a protective mechanism against oxygen deficiency and lipotoxicity, and hence inhibition of FA oxidation has been suggested as a therapeutic approach to HF. 1, 3 However, recent studies suggest a novel concept that a diet high in fat may prevent the progression of HF. 4, 5 Studies have shown that enhancement of FA utilization through feeding animals a high fat diet (HFD) attenuated cardiac dysfunction, [6] [7] [8] [9] while inhibition of FA utilization through genetic manipulation aggravated cardiac dysfunction in response to pressure overload. [10] [11] [12] These advances suggest that targeting cardiac FA utilization may be a potential strategy for the treatment of HF. FA oxidation occurs primarily in mitochondria that continually undergo fission and fusion. Evidence has shown that the balance between mitochondrial fission and fusion is strictly associated with their bioenergetics. [13] [14] [15] [16] On the one hand, mitochondrial fusion/fission balance can be tipped in either direction by changes in nutrient availability or by metabolic demands, e.g. cells tend to keep their mitochondria in fragmented state in a rich-nutrient environment and mitochondria tend to remain connected under starvation. [17] [18] [19] On the other hand, mitochondrial dynamics is also involved in the regulation of nutrient utilization. Generally, mitochondrial fusion allows efficient mixing of mitochondrial content and serves to optimize mitochondrial bioenergetics, while mitochondrial fission serves to suppress mitochondrial bioenergetics and contributes to mitochondrial quality control and maintenance of bioenergetics capacity. 14, 19 Unbalanced mitochondrial fusion/fission, such as mitochondrial fragmentation, occurs in response to stress and in diseases. 20, 21 It has been shown that mitochondrial fragmentation is a cause of HF and mitochondrial fragmentation-induced cardiac dysfunction can be reversed by feeding mice a HFD, 9 suggesting that the metabolic switch may be associated with the imbalanced mitochondrial fission/fusion in the failing heart. Although the molecules involved in mitochondrial dynamics have been well-documented, the underlying mechanism of mitochondrial fragmentation in the failing heart is poorly understood. Here, we found that suppressed FA utilization due to pressure overload is responsible for mitochondrial fragmentation via OPA1 cleavage and enhancing FA utilization through either HFD treatment or genetic manipulation restores mitochondrial morphology and improves cardiac function in the failing heart.
Methods

Animals and transverse aortic constriction surgery
Animal experiments were performed according to the National Institutes of Health Guidelines for the Use of Laboratory Animals, and were approved by Fourth Military Medical University Committee on Animal Care. Transverse aortic constriction (TAC) was used in C57 mice (male, 8 weeks) to establish pressure overload-induced HF as described previously. 22 Mice were anesthetized by continuous 1.5-2% isoflurane in 100% oxygen. Briefly, the aorta was approached via minimal sternal incision and a 7-0 ligature was placed around the vessel using a 27-gauge needle to ensure consistent occlusion. Sham-operated mice underwent the same surgery but without constriction. After surgery, the mice were fed on either control diet or HFD for 2 months. All the diets were obtained from Research Diets Inc. (NJ, USA). Control diet consists of 10% of calories derived from FA and HFD consists of 45% of calories derived from FA. The cardiac and mitochondrial functions were detected 2 months after the surgery. Unless otherwise specified, eight mice were used for each experiment/condition. For studying the survival of TAC mice, 50 mice were used for each group.
Adeno-associated virus infection
Serotype 9 adeno-associated virus (AAV9) vectors encoding CD36 or YME1L were provided by Hanheng Biotechnology (Shanghai, China). C57 mice (male, 4 weeks) were randomly chosen to receive a singlebolus tail vein injection of either AAV9 encoding CD36 (or YME1L) or AAV9 encoding RFP at 1*10 11 viral genomes per mouse. After 4 weeks, mice were subjected to TAC or sham surgery.
Determination of cardiac structure and function
Histological studies were performed as described previously. 23 Hearts from mice were excised after induction of anaesthesia with sodium pentobarbital (400 mg/kg, i.p.). Briefly, cardiac tissues were paraffin embedded and sectioned at a thickness of 5 lm for staining of hematoxylin and eosin. Hematoxylin and eosin staining was performed according to the manufacturer's protocols. Echocardiography to assess cardiac function was performed in mice with Vevo 770 High-Resolution Micro-Imaging System (Visual Sonics Inc, Toronto, Canada). Mice were anaesthetized with 1% isofluorane/oxygen administered through inhalation. M-mode and two-dimensional measurements were made as described previously. 24 
Transmission electron microscopy
Mice were anesthetized with sodium pentobarbital (400 mg/kg, i.p.) and cardiac tissues were collected and fixed in electron microscopy fixation buffer. Transmission electron microscopy was performed as described previously. 23 The samples were visualized using a Hitachi microscope (H7500 TEM, Japan). Mitochondrial size and number were measured using the open-source image analysis program ImageJ (NIH).
Cardiomyocytes isolation and culture
Single adult ventricular myocytes were enzymatically isolated from the hearts of male SD rats (150-200 g) as described previously. 25 Hearts were excised after induction of anaesthesia with sodium pentobarbital (200 mg/kg, i.p.). Freshly isolated cardiac myocytes were plated on culture dishes coated with laminin (Sigma) for 1 h and then the attached cells were cultured in M199 medium (Invitrogen, Carksbad, California). Experiments were performed within 12 h after isolation. For measurement of cardiomyocyte contraction, electrical field stimulation (5 ms square-wave pulses at 1 Hz) was applied via a pair of platinum electrodes as described previously, 26 and cells were perfused with Tyrode's solution at a rate of 3 ml/min. Neonatal ventricular myocytes were isolated from 1-day-old SD rats and cultured as described previously. 25 
Respiratory control ratio
Mitochondrial respiratory control ratio was evaluated by measuring oxygen consumption with a Clark-type oxygen electrode (Strathkelvin 782; Strathkelvin Instruments, UK) as described previously. 27 Briefly, hearts were excised after induction of anaesthesia with sodium pentobarbital (400 mg/kg, i.p.). Isolated mitochondria (80-100 lg) was mixed with respiration buffer with 2.5 mM succinate added as substrate and 2.5 lM rotenone as complex I inhibitor. State III and IV respiration rates were measured in the presence or after depletion of 200 lM ADP.
Respiratory control ratio was defined as the ratio of state III to IV respiratory rate.
Confocal imaging
An inverted confocal microscope (Zeiss LSM 800) with a 40Â, 1.3 NA oil-immersion objective was used for imaging. For BODIPY measurement, the indicator (5 lM) was loaded at 37 C for 15 min followed by three-time washing. The BODIPY fluorescence was reported by exciting at 488 nm and collecting the emission at >500 nm. For detection of mitochondrial morphology, the mitoTracker Green (0.5 lM) was loaded at 37 C for 15 min followed by three-time washing. The mitoTracker fluorescence was reported by exciting at 488 nm and collecting the emission at >500 nm. Cell length and cytosolic Ca 2þ transients were monitored continuously by placing the scan line along the long axis of the cell. The cytosolic Ca 2þ transients were measured by fluo4 (5 lM) with excitation at 488 nm and emission collection at >500 nm. For detection of mitochondrial reactive oxygen species (ROS), mitoSOX (5 lM) was loaded for 20 min and washed. The fluorescence was excited at 488 nm and emission was collected at 540-625 nm. All experiments were performed at room temperature (22-25 C).
Western blot
The protein expression and phosphorylation were measured using western blot as described previously. 27 The immunoblots were probed 
Statistical analysis
All values are presented as mean ± SEM. Data were compared with oneway ANOVA or two-way ANOVA, with all ANOVA tests followed by an unpaired t-test, as appropriate. Normal distribution of data was analyzed by Kolmogorov-Smirnov normality test. Bonferroni's correction for multiple comparisons was used. The survival data were analyzed using a log-rank test. Differences were considered significant when P < 0.05.
Results
Feeding TAC mice a HFD increased cardiac FA utilization and improved cardiac function and survival
To test whether increasing cardiac FA utilization provides protection against HF, we subjected both sham and TAC mice to a HFD. Compared with age-matched sham mice, TAC mice showed a 6.5% decrease in body weight ( Figure 1A) , a 97.6% increase in heart weight and a 114.0% increase in heart weight-to-tibia length ratio 2 months post surgery ( Figure 1B) . In addition, pressure overload impaired cardiac function as evidenced by the decreased left ventricular (LV) ejection fraction and the increased LV chamber diameter ( Figure 1C and see Supplementary material online, Table S2 ). HFD feeding restored body weight and decreased heart weight by 26.8% and heart weight-to-tibia length ratio by 24.7% in TAC mice ( Figure 1A and B). It also increased LV ejection fraction and normalized LV chamber diameter in TAC mice ( Figure 1C and see Supplementary material online, Table S2 ). More importantly, HFD feeding improved the 100-day survival of TAC mice by 24 .0% (P = 0.01, Figure 1D ). These results indicated that HFD exerted cardioprotective effects for TAC mice.
To determine whether the cardioprotection of HFD is associated with the enhanced FA utilization in the heart, we detected the circulating levels of FFAs and TG, which determine the rate of FA uptake by the heart. 28 Although pressure overload slightly increased both circulating levels of FFAs and TG ( Figure 1E and F), it significantly decreased the cardiac contents of both CD36 and CPT-1 b, which are key rate-limiting enzymes in FA utilization by the heart ( Figure 1G ). 28 CD36 is abundantly expressed in cardiomyocytes and is the predominant form of FA translocase in the heart. CPT-1 b is the key regulatory molecule in controlling the rate of FA uptake by mitochondria. In addition, pressure overload decreased the intramyocardial storage of lipids as evidenced by the decreased intramyocardial lipid droplets and TG contents, which have recently been identified as a significant source of fuel for mitochondrial oxidation in the heart 29, 30 ( Figure 1H and I). Feeding TAC mice a HFD increased the circulating levels of FFAs and TG, cardiac CD36 and CPT-1 b expressions, and intramyocardial lipid droplets and TG contents ( Figure 1E-I) . These results suggested that dietary fat increased cardiac FA utilization in TAC mice.
3.2
Cardiac-specific overexpression of CD36 protected the heart against pressure overload-induced HF It should be noted that besides enhancement of cardiac FA utilization, dietary fat also increased body weight, circulating FA and systemic insulin resistance ( Figure 1 , Supplementary material online, Figure S1 ). Thus, the other approach was used to specifically enhance cardiac FA utilization through cardiac-specific overexpression of CD36 using AAV9, an efficient and safe vector for cardiac gene transfer. 31 AAV9 infection induced a homogeneous expression of CD36 in cardiomyocytes (see Supplementary material online, Figure S2 ) and displayed no effects on body weight, circulating FA and systemic insulin sensitivity in sham mice ( Figure 2 and see Supplementary material online, Figure S3 ). CD36 overexpression increased cardiac contents of CD36 and CPT-1 b (Figure 2A) , as well as intramyocardial lipid droplets and TG in TAC mice ( Figure 2B and C). Meanwhile, CD36 overexpression restored the circulating levels of FFAs and TG in TAC mice ( Figure 2D and E). These results suggested that CD36 overexpression using AAV9 was a more specific approach for enhancement of cardiac FA utilization. Similar to HFD, CD36 overexpression increased body weight and decreased heart weight by 36.1% and heart weight-to-tibia length ratio by 22 .7% in TAC mice ( Figure 2F and G) . Furthermore, it improved the cardiac function as evidenced by the increased LV ejection fraction and the decreased LV chamber diameter in TAC mice ( Figure 2H and I, Supplementary material online, Table S3 ). These results reinforced the notion that upregulation of cardiac FA utilization exerted cardioprotection against pressure overload-induced HF. 
Enhancement of FA utilization attenuated mitochondrial fragmentation and improved mitochondrial function in the failing heart
We next examined the role of FA utilization in regulation of mitochondrial morphology in the failing heart. Pressure overload induced cardiac mitochondrial fragmentation as evidenced by the increased mitochondrial number and the decreased mitochondrial size in TAC mice ( Figure 3A) . It also decreased mitochondrial respiratory control ratio ( Figure 3B ) and ATP content ( Figure 3C ), while increased mitochondrial ROS ( Figure 3D) . Notably, the cardiac mitochondrial fragmentation and dysfunction were attenuated by both HFD and cardiac-specific overexpression of CD36 in Data are analyzed using one-way ANOVA in A, followed by unpaired t-tests. Data are analyzed using two-way ANOVA in B-D, followed by unpaired t-tests. *P < 0.05; **P < 0.01. Data are analyzed using one-way ANOVA in A, followed by unpaired t-tests. Data are analyzed using two-way ANOVA in (B)-(H), followed by unpaired t-tests. *P < 0.05; **P < 0.01. TAC mice (Figure 3A-H) . These results suggested that enhancement of cardiac FA utilization rebalanced mitochondrial dynamics in TAC mice.
Fatty acids regulate mitochondrial dynamics
To examine the underlying mechanism of the regulation of mitochondrial dynamics by FA, we next detected the contents of the major mitochondrial dynamics-related proteins. No differences in the contents of mfn1, mfn2, Drp1, fis1 and Drp1 phosphorylation were detected in TAC mice and both HFD and cardiac-specific overexpression of CD36 displayed no effects on these proteins ( Figure 3I-N) . Specifically, the dynamin-like GTPase OPA1, which processing is a central regulatory step coordinating mitochondrial fusion and fission in HF, 9 showed profound changes in TAC mice, and such changes could be reversed by both HFD and CD36 overexpression ( Figure 3I-P) . OPA1 can be cleaved from long (L-OPA1) to short (S-OPA1) forms by two mitochondrial proteases, OMA1 and YME1L. It has been suggested that L-OPA1 is required for mitochondrial fusion and accumulation of S-OPA1 accelerates mitochondrial fission. 9 Pressure overload decreased the contents of total OPA1, L-OPA1 and L-OPA1/S-OPA1, while it had no effects on the contents of S-OPA1 ( Figure 3I-P) . Imbalanced OPA1 processing was attenuated by both HFD and cardiac-specific overexpression of CD36 in TAC mice ( Figure 3I -P). Given that OPA1 processing accelerated OPA1 proteolysis, these results suggested that FA may regulate mitochondrial dynamics through inhibition of OPA1 cleavage.
FA inhibited OPA1 cleavage
We then examined the role of FA in the regulation of OPA1 processing in vitro. The main FA taken up by the heart is oleic acid (OA), followed by palmitic acid (PA). Incubation of either OA or PA for 2 h increased the contents of L-OPA1/S-OPA1 in a dose-dependent manner in isolated cardiomyocytes ( Figure 4A ), suggesting that FA inhibited OPA1 processing from L-OPA1 to S-OPA1. It has been suggested that ROS plays a critical role in pressure overload-induced mitochondrial dysfunction and OPA1 processing. 32, 33 Thus, we examined the effects of FA on cardiomyocytes under oxidative stress. Incubation of H 2 O 2 (10 lM) for 2 h decreased the contents of L-OPA1 and L-OPA1/S-OPA1 and increased the contents of S-OPA1 in isolated cardiomyocytes ( Figure 4B) . Interestingly, both OA and PA rescued the effects of H 2 O 2 on OPA1 processing in a dose-dependent manner in isolated cardiomyocytes ( Figure 4B) . Furthermore, both OA and PA (150 lM) attenuated mitochondrial fragmentation induced by H 2 O 2 ( Figure 4C) . As a result, FA incubation exerted protective effects on cardiomyocytes against oxidative stress, improving contractile function and survival of isolated cardiomyocytes ( Figure 4D and see Supplementary material online, Figure S4 ). These results indicated that FA inhibited mitochondrial fragmentation and improved contractile function through inhibition of OPA1 cleavage in cardiomyocytes under oxidative stress.
FA inhibited OPA1 cleavage through upregulation of YME1L
Treatment with OA or PA had no effects on OMA1 expression but increased YME1L expression in a dose-dependent manner in isolated cardiomyocytes ( Figure 5A ) In addition, both OA and PA attenuated the loss of YME1L contents in a dose-dependent manner in cardiomyocytes under oxidative stress (10 lM H 2 O 2 for 2 h) ( Figure 5B and C) . These results suggested that FA can increase YME1L expression in cardiomyocytes under both normal condition and oxidative stress. Knockdown of YME1L inhibited FA-induced upregulation of YME1L and L-OPA1/S-OPA1 in neonatal myocytes under oxidative stress ( Figure  5D-F) . In addition, both dietary fat and cardiac-specific overexpression of CD36 restored the pressure overload-induced decrease of YME1L content in TAC hearts ( Figure 5G) . Taken together, the results suggest that upregulated YME1L expression was responsible for inhibition of OPA1 cleavage and mitochondrial fragmentation by FA. It is reported that PPARs can be activated by FA and its activation increases the expression of genes that encode proteins responsible for FA-mediated signaling. 28, 34 Bioinformatic prediction suggested that
Yme1l1 has a PPARc response element (see Supplementary material online, Figure S5 ). We therefore tested whether FA upregulates YME1L expression through activation of PPARc. Both OA and PA increased the contents of PPARc in a dose-dependent manner in isolated cardiomyocytes ( Figure 5A ). In addition, knockdown of PPARc using siRNA silence inhibited FA-induced YME1L upregulation in neonatal myocytes under both control condition and oxidative stress ( Figure 5H) . Pressure overload decreased PPARc expression and both HFD and cardiac-specific overexpression of CD36 increased PPARc expressions in TAC mice ( Figure 5G ), suggesting that enhancing FA utilization upregulated YME1L expression through activation of PPARc.
Upregulation of YME1L expression exerted cardioprotection against pressure overload
To further confirm the role of YME1L in the cardioprotection provided by FA against HF, we specifically overexpressed YME1L in hearts of TAC mice using AAV9. Cardiac-specific overexpression of YME1L increased the contents of YME1L and L-OPA1/S-OPA1 and attenuated mitochondrial fragmentation in TAC mice ( Figure 6A and B), accompanied with increased mitochondrial respiratory control ratio ( Figure 6C ) and cardiac ATP level ( Figure 6D ). In addition, cardiac-specific overexpression of YME1L decreased heart weight by 24 .6% and heart weight-to-tibia ratio by 21 .7% in TAC mice ( Figure 6E) . It also increased LV ejection fraction and decreased chamber diameter in TAC mice ( Figure 6F and see Supplementary material online, Table S4 ). We next examined whether the restoration of mitochondrial morphology has effect on cardiac FA utilization. Restoration of mitochondrial morphology with cardiacspecific overexpression of YME1L increased the contents of CD36 and CPT-1 b ( Figure 6G ), as well as intramyocardial storage of lipids as evidenced by the increased intramyocardial lipid droplets and TG in TAC mice ( Figure 6H-I) , suggesting that improvement of mitochondrial dynamics increased FA utilization in the TAC heart.
Discussion
Metabolic defects play a crucial role in the initiation and progression of HF and metabolic intervention has been proposed as a potential therapeutical strategy for HF. Here we show that enhancing cardiac FA utilization ameliorates mitochondrial fragmentation and cardiac dysfunction in pressure overload-induced HF. FA, apart from being a predominant oxidative substrate, plays an important role in the regulation of mitochondrial dynamics through inhibition of OPA1 cleavage. Our findings suggested that suppressed cardiac FA utilization contributes to mitochondrial fragmentation and cardiac dysfunction in response to pressure overload via unbalancing OPA1 processing. A schematic figure illustrating the role of FA in the regulation of mitochondrial dynamics is shown in Figure 7 .
Although lipid-induced cardiac toxicity clearly can be created, a number of clinical and experimental issues regarding the role of FA utilization in the development of HF are controversial. Animal studies revealed that 
feeding a HFD to healthy rodents generally has no adverse effects on hearts if there is no concomitant obesity, [35] [36] [37] and only chronic utilization of supra-physiological levels of FA can result in cardiac dysfunction. [38] [39] [40] [41] Epidemiological studies also provided evidence that dietary fat intake is not associated with cardiovascular diseases including HF. [42] [43] [44] In addition, a recent study recruiting 135 335 subjects from 18 countries showed that dietary fat intake is related to lower total mortality. 44 A recent animal study also showed that dietary fat intake extends longevity and healthspan in mice. 45 These advances suggested that enhancement of FA utilization may exert health-promoting effects in both humans and animals. Consistent with previous reports, 4, 5, 9 our findings demonstrated that feeding mice a HFD prevents the development of HF. Therefore, there should be a major shift in the recommendations for dietary macronutrients for people with HF or higher risk of HF. HFD induced an increase in systemic FA utilization and a decrease in systemic insulin sensitivity. As dietary fat is frequently a confounding factor, to exclude the systemic effects of FA, we also used cardiac-specific overexpression of CD36 that is a more specific approach for enhancement of cardiac FA utilization. Different from HFD, cardiac-specific overexpression of CD36 showed little effects on circulating FA and systemic insulin sensitivity in sham mice. However, CD36 overexpression exerted similar cardioprotective effects to HFD in the prevention of pressure overload-induced HF. Both approaches significantly enhanced cardiac FA utilization and improved cardiac structure and function in TAC mice, indicating the protective effects of dietary fat against HF rely on the upregulation of cardiac FA utilization in the failing heart.
FA is generally regarded as a predominant oxidative substrate. Here, our results provided evidence that FA also plays an important role in the regulation of myocardial mitochondrial dynamics in HF. Changes in mitochondrial dynamics, which is under the control of specific mitochondrial fission and fusion proteins, have been implicated in cell division, embryonic development, apoptosis, autophagy and metabolism. Mitochondrial fragmentation has recently been suggested as a cause of HF and targeting mitochondrial fragmentation might be a promising strategy for intervention of HF. 9, 46 However, the underlying mechanisms of mitochondrial fragmentation in HF remain largely unknown. Our results showed that the enhancement of cardiac FA utilization inhibited mitochondrial fragmentation and improved mitochondrial function in both TAC mice and isolated cardiomyocytes, suggesting that the suppressed FA utilization is responsible for mitochondrial fragmentation in the failing heart. Although mitochondrial fusion occurs infrequently in adult cardiomyocytes, 47 it is indispensable in mitochondrial quality control by allowing content mixing and preventing the accumulation of mitochondrial damage. 48 Recent studies suggested that the proteolytic processing of OPA1 is emerging as a critical regulatory step to balance mitochondrial fusion/fission in cardiomyocytes. 9, 46 Uncleaved, fusion-active L-OPA1 is anchored to the inner member of mitochondria and is sufficient to mediate mitochondrial fusion, while accumulation of S-OPA1 is suggested to promote mitochondrial fission. We found that pressure overload decreased the content of L-OPA1 but not S-OPA1 and enhancement of FA utilization restored the content of L-OPA1, suggesting that FA regulates OPA1 processing in the heart. In addition, in vitro studies in isolated cardiomyocytes confirmed that FA regulates OPA1 processing and increases the content of L-OPA1 under both normal condition and oxidative stress. Sadoshima's group recently reported that Drp1 content is decreased in mitochondria, which contributes to mitochondrial dysfunction in HF. 49 Our results only showed that enhancement of FA utilization had no significant effects on Drp1 expression, while whether FA metabolism regulates Drp1 localization has not been studied. Balanced OPA1 cleavage by YME1L and OMA1 at two distinct sites leads to the accumulation of both L-OPA1 and S-OPA1 and maintains mitochondrial morphology. The effects of YME1L and OMA1 on OPA1 cleavage are not independent. Here, we found that pressure overload only decreased YME1L expression with little effect on OMA1 expression. It is suggested that the loss of YME1L could activate OMA1 and trigger stress-induced OPA1 processing, resulting in the accumulation of S-OPA1 and mitochondrial fragmentation in hearts. 9 We found that FA increased the expression of YME1L in a dose-dependent manner in isolated cardiomyocytes, contributing to the effects of FA in the regulation of OPA1 processing. Moreover, FA increases YME1L expression through activation of PPARc. PPARs are important regulators of cardiac metabolism and PPAR agonists can improve cardiac function in animal models of diseases. 50 In addition, our results also provided evidence that cardiac-specific overexpression of YME1L improved mitochondrial and Figure 7 Schematic figure illustrating that suppressed FA utilization contributes to cardiac dysfunction in response to pressure overload. FA plays an important role in the regulation of mitochondrial dynamics through activation of nuclear receptor PPARc which increases the expression of YME1L. YME1L balances OPA1 processing and inhibits mitochondrial fragmentation in the heart. Enhancement of cardiac FA utilization exerts cardioprotection against pressure overload-induced HF. The black arrows and words indicate normal status, and the red arrows and words indicate heart failure Fatty acids regulate mitochondrial dynamics cardiac functions in TAC mice. The improved mitochondrial morphology in turn enhanced cardiac FA utilization in TAC mice, suggesting that mitochondrial dynamics and FA utilization reciprocally influence each other in the heart. One of the limitations of our study is the lack of direct evidence on whether FA-regulated mitochondrial dynamics is dependent on FA oxidation. The role of energy supply from FA oxidation in FAprovided cardioprotection has not been studied. In addition, it has been reported that calcium also plays an important role in the regulation of mitochondrial dynamics and mitochondrial calcium disposal is abnormal in HF. 51, 52 Whether there is a crosstalk between FA metabolism and calcium disposal in the failing heart needs to be further investigated. Taken together, suppressed FA utilization by the failing heart contributes to cardiac dysfunction via unbalancing OPA1 processing and enhancement of FA utilization exerts protective effects against pressure overload-induced HF. FA plays an important role in the regulation of mitochondrial dynamics through activation of nuclear receptor PPARc, which increases the expression of YME1L. YME1L inhibits OPA1 cleavage and mitochondrial fragmentation in HF. Therefore, cardiac metabolic intervention may be a promising approach for improvement of mitochondrial and cardiac functions in the failing heart.
